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Huntington’s disease (HD) is a devastating, fatal, autosomal dominant condition in which
the abnormal gene codes for a mutant form of huntingtin that causes widespread neu-
ronal dysfunction and death.This leads to a clinical presentation, typically in midlife, with a
combination of motor, psychiatric, cognitive, metabolic, and sleep abnormalities, for which
there are some effective symptomatic therapies that can produce some transient beneﬁts.
The disease, though, runs a progressive course over a 20-year period ultimately leading to
death, and there are currently no proven disease modifying therapies. However whilst the
neuronal dysfunction and loss affects much of the central nervous system, the striatum is
affected early on in the disease and is one of the areas most affected by the pathogenic
process. As a result the prospect of treating HD using neural transplants of striatal tissue
has been explored and to date the clinical data is inconclusive. In this review we discuss
the rationale for treating HD using this approach, before discussing the clinical trial data
and what we have learnt to date using this therapeutic strategy.
Keywords: Huntington’s disease, neural transplantation, clinical studies
INTRODUCTION
Huntington’s disease (HD) is a genetic, autosomal dominant, trin-
ucleotide repeat disorder caused by an expansion of CAG repeats
in exon 1 of the huntingtin gene and the formation of abnormal
huntingtin protein with N-terminal polyglutamine tracts (The
Huntington’s Disease Collaborative Research Group, 1993). It is
characterized by progressive neurodegeneration within the cen-
tral nervous system (CNS), with areas such as the striatum and
the cerebral cortex traditionally being affected at a relatively early
stage, although this is having to be revised in the light of the recent
TRACK-HD data (Tabrizi et al., 2009, 2011; Ross and Tabrizi,
2011). Clinically, the disease manifests with the development of
movement abnormalities and cognitive andpsychiatric symptoms,
which gradually deteriorate and invariably lead to severe disabil-
ity, alongwith earlymetabolic, and sleep abnormalities (Goodman
et al., 2008, 2011; Wood et al., 2008; Goodman and Barker, 2010).
Although knowledge has advanced since the gene for HD was
identiﬁed, the biochemical and cellular pathophysiology of the
mutant huntingtin gene and protein and their wider effects are
complex and still not well understood, leading to difﬁculties in the
development of curative, or disease modifying therapies (Ross and
Tabrizi, 2011). Thus, current treatments for HD remain mainly
symptomatic and alternative strategies, including cell replace-
ment by fetal striatal tissue transplantation have continued to be
explored.
Before the identiﬁcation of the genetic basis of HD and the
research that has stemmed from this, HD was thought of as a
disease which primarily involved signiﬁcant atrophy and degen-
eration of the striatum-particularly the medium spiny neurons.
Whilst it is now recognized that the condition has a much more
diffuse pathology from disease onset, it is nevertheless clear that
the striatum is a major site of pathology and thus could be a target
for cell replacement therapies. As such the rationale developed that
replacing the lost neurons through striatal grafting could work for
this condition, if the cells could be shown to survive and connect
appropriately with the host brain and by so doing recreate the stri-
atal circuitry. This was originally shown experimentally in various
older types of animal models of HD.
THE EXPERIMENTAL EVIDENCE FOR SUCCESSFUL STRIATAL
ALLOGRAFTING IN ANIMAL MODELS OF HD
Prior to the discovery of the gene for HD and the subsequent
generation of transgenic models, the main animal model of HD
involved excitotoxic lesions of the striatum (Coyle and Schwarcz,
1976; DiFiglia, 1990; Ferrante et al., 1993). Using this model it
was shown that allografts of fetal striatal tissue could survive the
transplantation process and become integrated in the host brain
(Wictorin, 1992). This integration was shown using an array of
labeling techniques, and clearly showed that the striatal projec-
tion neurons that developed out of the transplant received cortical
and nigral afferents, whilst also projecting to the pallidum and
nigra (Clarke et al., 1988; Campbell et al., 1993; Clarke and Dun-
nett, 1993; Dunnett, 1999). This “circuit reconstruction” led to
behavioral improvements in these animals, and provided evidence
that such an approach could, in theory, work in patients with HD
(Isacson et al., 1984; Dunnett et al., 1988; Reading and Dunnett,
1995).
These early rodent studies were important in showing a proof
of concept that striatal allografts could replace and restore func-
tion in a “diseased striatum.”However it must be realized that the
tissue grafted contains more than just striatal tissue, as typically
the whole ganglionic eminence (WGE) is dissected and implanted
and this structure gives rise to a range of non-striatal structures
such as the pallidum and cortex (Graybiel et al., 1989; Watts et al.,
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2000a). As such grafts of WGE tissue produced heterogeneous
transplants of which only a part are striatal in structure and at
least 40% of the total transplant needs to be “striatal” in nature
in order for an effect to be seen (Nakao et al., 1996; Watts et al.,
2000b). The contribution of this non-striatal tissue to the efﬁ-
cacy, or not, of the graft is unknown, but attempts to circumvent
this with more selective dissections [e.g., dissection of the lateral
part of the lateral ganglionic eminence (LGE)], whilst increasing
the percentage of striatal tissue within the grafts, has failed to
enhance or even reproduce the behavioral effects of WGE trans-
plants (Freeman et al., 1995; Peschanski et al., 1995; Brundin et al.,
1996; Brasted et al., 1999). In addition these models work on the
premise that striatal pathology lies at the heart of HD, and that
excitotoxic lesions of this structure, accurately or at least ade-
quately models disease. This is a big assumption given what we
now know about HD, and indeed similar allotransplants into a
commonly used transgenic mouse model of HD (the R6/2 mouse)
did not show any beneﬁts (Dunnett et al., 1998). This is important
because ultimately for striatal allografts to work they must form
connections to and from the host brain and this process may be
compromised if those structures to which they connect are them-
selves affected by the HD disease process (see below Post-mortem
Studies).
Nevertheless by the mid-1990s, when the ﬁrst transgenic mod-
els of HD were emerging, sufﬁcient data had been acquired from
the rodent excitotoxic models, to move toward non-human pri-
mate studies. In 1998 two groups reported their ﬁndings in this
area, showing that fetal striatal allografts placed into the excito-
toxic lesioned striatum of marmosets and macaques behaved in an
analogous fashion to that seen in similar rodent studies (Kendall
et al., 1998; Palﬁ et al., 1998). It was against this background that
clinical studies commenced, even though the negative transgenic
model transplant study had yet to be done and published and some
of these early clinical studies were done at centers not previously
involved with the experimental animal transplantation work.
CLINICAL STUDIES OF STRIATAL ALLOGRAFTING IN
HUNTINGTON’S DISEASE
The positive results from animal models led to a number of small
open-label studies of fetal striatal transplantation in HD patients
at several centers around the world with the expectation that
the grafted tissue would work by recreating local striatal circuits,
rather than through any neurotrophic effects or an enhancement
of endogenous repair processes. These studies are presented in
terms of where they were done, as each center tended to adopt
their own techniques for tissue preparation and implantation as
well as trial design.
Sramka et al. (1992) in Bratislava published an early report
on fetal neural transplantation into the caudate nucleus of HD
patients using stereotactic neurosurgery. Four HD patients with
relatively severe disease received transplants of “mesencephalic”
tissue from two to three embryos into the caudate nucleus bilat-
erally. Immunosuppression was provided with cyclosporine and
postoperatively the authors observed a reduction in the amplitude
and frequency of hyperkinesia.
This was followed by Madrazo et al. (1995) in Mexico. They
published case reports of fetal striatal transplantation in two
patients with HD. This study involved a 39-year old female with
disease duration of 9 years and a 29-year old male with disease
duration of 5 years. Fetal striatal tissue (aged 13weeks for the
ﬁrst patient and 12weeks for the second) was transplanted into
the right caudate nucleus followed by immunosuppression with
cyclosporine A and prednisolone. No surgical complications were
reported at 33 and 16months postoperatively for the two patients
who appeared to have a slower or more stable disease progression
as compared to their preoperative state.
Quinn et al. (1996) established a protocol by which to assess the
safety and efﬁcacy of neural transplantation in HD across stud-
ies and centers, – the Core Assessment Program for Intracerebral
Transplantation in HD – the CAPIT-HD protocol. This has been
used by many centers and has been adopted by most of those trials
that we will now discuss (Table 1).
LOS ANGELES, USA
Philpott et al. (1997) and Kopyov et al. (1998) reported a safety
study on three HD patients in Los Angeles. The HD patients
were non-demented males, age 25–48, with disease duration of
3–9.5 years, and total Uniﬁed Huntington’s Disease Rating Scale
(UHDRS) motor scores of 30–56. Fetal striatal precursor tissue
from the LGE of ﬁve to eight donors aged 8–10weeks was trans-
planted bilaterally into the caudate and putamen. At 12months
follow up post-surgery there was one bone ﬂap infection, but no
major unexpected adverse effects. Overall, UHDRS motor scores
improved slightly to 18–30, but in one patient their preoperative
myoclonus continued to worsen. Psychiatric symptoms decreased
in frequency and intensity in 2/3 cases and at 4–6months, some
scores improved on measures of cognitive functioning.
Magnetic resonance imaging (MRI) scans showed survival and
growth of grafts, but at 12months one patient developed a hypo-
dense area in the right striatum which was thought to represent
porencephaly secondary to delayed graft necrosis or an asymp-
tomatic infarct. Overall, the trial concluded that fetal striatal
transplantation in HD was possible without major unexpected
complications. (See also Post-mortem Studies below).
FRANCE
Bachoud-Levi et al. (2000a,b, 2006) reported on fetal striatal trans-
plantation in ﬁve HD patients in France in 2000. Pre-transplant,
the patients had a disease duration of 2–7 years, UHDRS motor
scores of 20–91, total functional capacity (TFC) of 11–12 and all
but one had little cognitive impairment. Interestingly, their rate
of progression was quite rapid coming up to the grafting itself
(Lazic and Barker, 2004). WGE tissue from 7.5- to 9-week-old
fetuses was transplanted into the right and left (1 year apart) cau-
date and putamen. Immunosuppression was with cyclosporine
(stopped 6months post second graft), azathioprine, and pred-
nisolone (gradually stopped up to 1 year post second graft). Two
years after receiving the ﬁrst transplant, three patients showed
improvement or stability in the UHDRS motor score, TFC,
and neuropsychological tests of attention and executive function
along with some neurophysiological tests, compared to control
HD patients. 18F-ﬂuorodeoxyglucose (FDG) positron emission
tomography (PET) imaging showed increased striatal and frontal
cortical metabolic activity at 2 years post grafting in these three
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patients, while the other two patients had no evidence of improve-
ment both clinically and on PET imaging (Gaura et al., 2004).
The authors concluded that metabolically active grafts were sur-
viving in the striatum and could underlie the clinical beneﬁts seen
in the three patients. At 2–6 year follow up times (Bachoud-Levi
et al., 2006) these three patients were seen to demonstrate relative
stability in motor features (apart from dystonia), non-timed cog-
nitive, and functional assessments, with slightly decreased striatal
and maintained frontal metabolic activity on PET imaging. One
other patient improved initially, but then deteriorated following
the appearance of a putamenal cyst onMRI. The remaining patient
continued to decline throughout.
This group are currently involved in an on-going European
Phase II trial of fetal striatal transplantation in HD1. An ancillary
study to the main trial has reported on 13 patients aged 39–55,
disease duration 4–11 years, who have received fetal striatal trans-
plants (bilaterally in 12 patients, 3 weeks–3months apart) (Krys-
tkowiak et al., 2007). Immunosuppression involved cyclosporineA
(stopped within the ﬁrst year post bilateral grafting) and azathio-
prine and prednisolone (gradually decreased and stopped in the
following months). Two patients developed subdural hematomas
(SDHs) postoperatively and one had a cerebral infection. In addi-
tion, one patient showed evidence of an on-going rejection process
clinically, immunologically, and on imaging at 14months post-
transplant, which reversed with further immunosuppressive ther-
apy. Four other patients developed evidence of alloimmunization
without rejection. The extent to which this will be a signiﬁcant
complication of this approach is not known at the present time,
but may become more obvious in the on-going larger trial.
FLORIDA, USA
Hauser et al. (2002) reported on fetal striatal transplantation
in HD patients in Florida, USA. Seven non-demented patients,
aged 28–64, 2–12 years from diagnosis, with a mean UHDRS total
motor score of 32.9 and a TFC of 6.6, received far lateral LGE
grafts from 8- to 9-week-old fetuses into the caudate and putamen
bilaterally. Immunosuppression with cyclosporine A was given for
6months. Three patients developed SDHs post operatively, with
two requiring surgical evacuation. This was thought to be due
to the increased cortical atrophy seen in HD and intraoperative
CSF loss, highlighting the risks associated with surgery on more
advanced HD patients. At 12months follow up, mean UHDRS
motor scores (29.7± 7.54) and TFC (7.0± 2.16), indicated no
signiﬁcant improvement or worsening, which may reﬂect some
clinical beneﬁt in the context of the natural progression of HD.
Post hoc analysis excluding patient 5 (who deteriorated after the
development of the SDHs) indicated a signiﬁcant improvement in
UHDRS motor scores. FDG and (11C)-Raclopride PET imaging
demonstrated maintenance of lentiform metabolic activity and
putamenal D1 receptor binding. Some decrease in caudate D1 and
D2 receptor binding and putamenal D2 binding was seen at 6–
18months, with a signiﬁcant loss of D2 binding at 2 years (Hauser
et al., 2002; Furtado et al., 2005). Several of these cases have now
come to post-mortem (see below) with ﬁndings that ﬁt well with
the PET scanning data.
1http://clinicaltrials.gov/show/NCT00190450
UK
Rosser et al. (2002) reported on a UK trial of fetal striatal trans-
plantation in HD. Four patients with mild to moderate HD each
had WGE cell suspensions from one 8.5- to 12-week-old fetus
transplanted into the caudate and putamen of the non-dominant
hemisphere. Triple immunosuppression with prednisolone,
cyclosporine, and azathioprine was used. At 6months post-
transplant, there was a non-signiﬁcant trend toward improvement
in the UHDRS motor score, but no signiﬁcant changes in hand
tapping, functional capacity, or neuropsychological test scores.
MRI showed appropriate positioning and growth of grafts. Up to
6months, predicted complications from the immunosuppression
were seen and included renal impairment and anemia.
These four patients went onto have striatal transplants on the
contralateral side on average 22.5months after the ﬁrst transplant.
One other patient was transplanted bilaterally simultaneously.
The patients were followed up with the CAPIT-HD protocol
and compared to non-transplanted HD patients. At 2 years post-
transplant theywere observed to showno signiﬁcant improvement
(Unpublished data; Barker and Swain, 2010).
LONDON, UK
Reuter et al. (2008) reported on two patients receiving fetal stri-
atal allografts in HD. One male and one female patient with
disease duration 4–6 years, received WGE cell suspension grafts
from two to three 9- to 10-week-old fetuses into the caudate
and putamen bilaterally (2months between sides). Immunosup-
pression was planned to involve prednisolone for 1month and
cyclosporine for 1 year. Patient 1 was followed up with the CAPIT-
HD protocol for 66months and displayed a gradual but marked
improvement which was also reported subjectively. His UHDRS
score improved from 54 preoperatively, to 8 at 66months, with
signiﬁcant improvements in his TFC, Beck Depression score, and
some cognitive task scores. (11C)-RaclopridePET imaging showed
evidence for increased striatal D2 receptor binding at 6months,
which then decreased at a rate similar to that seen in non-grafted
HD patients, but remained above baseline at 2.5 years. This was
thought to relate to graft survival within a degenerating stri-
atal complex. Cyclosporine was discontinued at 3months due to
renal complications. Patient 2 did not demonstrate any signiﬁcant
change clinically or on imaging post-transplantation and unfortu-
nately developed an acute meningoencephalitic illness following a
fall 2 weeks after stopping the cyclosporine.
GERMANY
Capetian et al. (2009) reported on the case of a 42-year old
male HD patient who underwent fetal striatal transplantation as
part of the German component of the European HD phase II
study. At baseline he had moderate chorea, with a normal psy-
chopathological status. WGE tissue from one 8- to 9-week-old
fetus was transplanted into the caudate and putamen bilater-
ally, 1month apart and standard triple immunosuppression was
used. At 6months post-transplantation, there was no signiﬁ-
cant difference in the UHDRS or cognitive score, but he showed
evidence of slight depression. He died of unrelated causes at
6months post-transplantation and the histology of the transplant
is discussed below.
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ITALY
Recently Gallina et al. (2008, 2010) reported on four cases of
fetal striatal transplantation in HD. The patients aged 33–53
were 5–8 years into their illness and each had WGE tissue from
one 9- to 12-week-old fetus transplanted into the caudate and
putamen bilaterally, 2months apart. Prednisolone, cyclosporine,
and azathioprine immunosuppression was used. The patients had
combinations of motor dysfunction (chorea, dystonia), cogni-
tive working memory problems, and mild psychiatric symptoms
pre-transplant. On follow up, the patients generally showed mild
improvements in UHDRS scores at 1 year post-transplant, which
remained relatively stable at 2 years. However, no signiﬁcant func-
tional beneﬁt was evident and one patient’s postoperative course
was complicated by the development of a thigh abscess.
Magnetic resonance imaging and PET imaging showed macro-
scopic growth of metabolically active, striatal – like tissue with
extension beyond the deposition site in six of eight grafts and
additional development of new tissue connecting the grafts with
the frontal cortex and the ventral striatum. There was some
reported increase in D2 receptor binding in three patients as
observed with (123)IBZM-SPECT imaging. The authors report
that they found no clinical or imaging evidence of uncontrolled
graft growth. However in relation to this study, Freeman et al.
(2011) have discussed the concern of graft overgrowth, the impor-
tance of optimizing donor, and grafting conditions and other key
technical issues involved in ensuring the safety of fetal neural
transplantation using this approach in HD.
CLINICAL STUDIES OF STRIATAL XENOGRAFTING IN
HUNTINGTON’S DISEASE
The use of fetal striatal tissue for transplantation brings with it
signiﬁcant ethical issues and limitations in the amount of tissue
available at any one time. Xenotransplantation, with the use of
porcine neural tissue may avoid some of these issues and one
clinical study has been reported so far (Fink et al., 2000). In this
study 12 HD patients received 24 million fetal porcine striatal
cells into the striatum unilaterally. One year post-transplantation,
they exhibited a favorable safety proﬁle, but there was no signif-
icant change in the TFC score. This is not surprising given what
we know about the survival of porcine tissue in the much less
immunologically challenging situation in the laboratory (Barker
and Widner, 2004).
POST-MORTEM STUDIES OF STRIATAL ALLOGRAFTING IN
HUNTINGTON’S DISEASE
Several centers have now reported post-mortem analyses on HD
patients with fetal striatal transplants.
FLORIDA, USA
The ﬁrst post-mortem report (Freeman et al., 2000) related to a
patient who received bilateral LGE transplants in Hauser et al.’s
(2002) study in Florida, USA. Three grafts were placed in the right
putamen,with one in the right caudate,while the left putamen and
caudate received four and two grafts respectively. He showed bene-
ﬁt in chorea and gait scores post-transplant, but died at 18months.
Post-mortem analysis identiﬁed three graft sites in the right puta-
men, two in the left putamen, and one in the left anterior limb of
the internal capsule, indicating survival of grafts 12months after
stopping immunosuppression. There was evidence of markers of
graft striatal differentiation and host dopaminergic innervation
of the graft but no evidence of immune rejection or aggregated
huntingtin in grafted tissue.
Three other patients transplanted at the same center (patients
1, 3, and 5; Hauser et al., 2002) came to post-mortem 10 years
post-surgery (Cicchetti et al., 2009). They had received four to six
grafts into each putamen and one to two grafts into each caudate
(Hauser et al., 2002). Graft survival was very poor in patient 3,
with only 1 (putamenal graft) of 16 transplants identiﬁed at post-
mortem. In the other two patients, there was complete loss of all
caudate grafts, but surviving putamenal grafts displayed areas with
striatal markers (P-zones). These regions contained typical striatal
projection neurons and interneurons, with the projection neurons
appearing less healthy compared to the interneurons. This pattern
of neuronal degeneration was noted to mimic that seen in HD and
the authors concluded that this suggested disease-like neuronal
degeneration was occurring in genetically unrelated striatal grafts.
Host cortical glutamatergic projections were found to be closely
apposed to striatal projection neurons and there appeared to be
an on-going immune response. Although the astroglial response
respected transplant boundaries, activated microglia were seen
within the striatal P-zones, with some indication of potential
phagocytosis of neuronal elements. There was no evidence of
abnormal huntingtin aggregation within the graft (Cicchetti et al.,
2009, 2011).
LOS ANGELES, USA
Keene et al. (2007) reported on the post-mortem results of two
patients transplanted at the Los Angeles center. Both patients
appeared moderately impaired at transplantation. Patient 1
received two grafts in the right putamen, three in the left putamen,
and one in the left caudate. He developed bilateral SDHs 2months
post operatively, but was lost to follow up and died 79months
post-transplantation. Patient 2 received three grafts per putamen
and one graft per caudate. She initially displayed apparent slower
progression at 3months post-transplant, before continuing to
progress at a rate typical for HD and died 74months after surgery.
Post-mortem studies showed similar ﬁndings in both patients. All
grafts, except the left caudate graft in patient 2, were identiﬁed
and consisted of neurons and dense neuropil, with few astrocytes,
and microglia. Neurons expressed markers consistent with striatal
neuronal differentiation and although there was some apparent
host dopaminergic innervation of the graft, evidence of graft to
host innervation was scant. Neuronal intranuclear polyubiquiti-
nated inclusions, characteristic of HD pathology, were absent in
the grafts.
Keene et al. (2009) also reported a case of fetal striatal trans-
plantation at the same center which showed evidence of graft
overgrowth at post-mortem. A 29-year old female HD patient
with mild motor, cognitive, and psychiatric symptoms received
9- to 10-week-old fetal LGE transplants bilaterally (four in each
putamen and one in each caudate). In addition, based on some
data suggesting the possible neurotrophic beneﬁts of peripheral
nerve co-grafts (Watts et al., 1995, 1997), autologous sural nerve
was also implanted into the most posterior right putamenal graft
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site. She received cyclosporine immunosuppression for 12months.
She showed improvement and stabilization of the UHDRS motor
and behavior scales and in some other indices up to 2 years post-
transplant, but then developed upper motor neuron signs, with
MRI evidence of a cyst and a nodular mass in the left and right
putamen respectively. HD disease features also then continued to
progress and she died around 121months post-transplantation.
Post-mortem revealed graft overgrowth,with ﬁvemass lesions and
two cysts in the right caudate and putamen and three mass lesions
andone large cyst in the left caudate andputamen.Themasses con-
tained unorganized neuropil and a diffuse population of neurons,
with islands of reactive astrocytes and scattered oligodendrocytes.
The authors reported no evidence of on-going mitotic activity and
interpreted the graft overgrowth as an excess of “normal” graft tis-
sue, rather then neoplastic proliferation. Factors inﬂuencing this
outcome were considered to include original graft composition,
host factors, and possibly effects of the sural nerve graft. Generally
poor graft–host integration, lack of immune rejection of allografts
and absence of graft inclusion pathology were also reported.
GERMANY
Post-mortem results of the case described by Capetian et al. (2009)
in Germany have also been reported. The patient received two fetal
WGE grafts with two trajectories into the head of the caudate, two
trajectories into the pre-commissural putamen and one trajec-
tory into the post-commissural putamen, bilaterally. The patient
died of unrelated causes at 6months post-transplant and post-
mortem showed evidence of surviving grafts along all trajectories,
with increasing maturity from the core to the periphery. There was
host dopaminergic innervation of the graft and some migration of
graft neuroepithelial cells into the host. Local inﬂammatory inﬁl-
trates and an increased surrounding glial reaction were seen with
perivascular cufﬁng of lymphocytes in response to grafted cells.
Based on the post-mortem studies so far, fetal striatal trans-
plants in HD appear to display poor long-term survival. The
reasons for this are not known, but allograft immunoreactivity,
excitotoxicity, and targeted microglial responses have been sug-
gested as potential factors in this poor survival (Cicchetti et al.,
2011). This has obvious implications for the long-term therapeu-
tic efﬁcacy of striatal transplantation in HD, as it would suggest
that any cell placed into the HD brain is likely to succumb to the
disease process in the tissue into which it is placed as the grafts try
to integrate.
CLINICAL CHALLENGES FOR STRIATAL ALLOGRAFTING IN
HUNTINGTON’S DISEASE
Unlike ventral mesencephalic allografting for Parkinson’s disease
(PD), the case for neural grafting with fetal striatal tissue for HD
remains unproven. There are case reports of beneﬁts that can last
for years, but there is also much data suggesting that it does not
work in the long term and post-mortem data suggesting that the
grafts eventually succumb to thedisease process. This raises a num-
ber of questions and challenges in using this approach for HD,
including:
• Why graft only the striatum when the disease affects many areas
of the CNS from disease onset?
• How can the graft survive and integrate when it is being placed
into a hostile environment where the disease process is well
established?
• What contribution does the non-striatal tissue in the graft make
to the efﬁcacy or otherwise of the transplant?
• If neural grafting is to be attempted in HD, when in the disease
process should it be done?
• Why bother using such an approach when a more logical one
would be to target the pathogenic cascade downstream of the
mutant gene and the protein it codes for?
• How can the beneﬁts of cell therapy be properly assessed in
small numbers of HD patients, each of whom may progress
rather differently from each other?
We will now brieﬂy deal with each of these issues in turn.
Why graft only the striatum when the disease affects many
areas of the CNS from disease onset?
It is now well recognized that HD has a diffuse pathology from
the onset and that whilst the striatum is affected early on and
signiﬁcantly, it is not the only site of pathology. However, the
fact that it is a majorly affected site does at least give some cre-
dence to targeting it with replacement therapies, especially given
some of the experimental data in animal models of HD. Indeed
in the ﬁeld of PD, it is now recognized that the disease process
involvesmany systemoutside the dopaminergic nigrostriatal path-
way, but this does not mean that targeting this latter pathway is
without effect (Brundin et al., 2010). So the same could be true
of HD, neural striatal allografting is not trying to cure patients
of HD, it is simply trying to restore one part of a more global
CNS disorder that does have major striatal pathology as part of
that process. The question then arises as to how much of the
features of HD are dependent on striatal pathology, as opposed
to pathology at other CNS sites, and how signiﬁcant are those
features to the patients quality of life (Tippett et al., 2007; Ho
et al., 2009; Thu et al., 2010). This is not known, but at least
some of the problems seen in this disorder do have a striatal
origin and thus targeting this structure for cell replacement is
not in itself a bad idea, it just has limited potential to help the
patient.
How can the graft survive and integrate when it is being
placed into a hostile environment where the disease process is
well established?
This has only recently become an issue as the post-mortem
studies emerge, and does represent a major problem to the ﬁeld.
Experimentally grafts of fetal striatal tissue have been shown to
survive and integrate well in the excitotoxic model of HD (Clarke
and Dunnett, 1993), but this is very different from the genetic dis-
order where all cells are affected to a degree by the mutant gene
and its product. Studies in HD transgenic models have been very
limited, but at least clinically in those grafts that have been looked
at years after implantation, there is evidence that they are not sur-
viving. The reasons for this are not known, although a number
of theories have been proposed (Cicchetti et al., 2011). Neverthe-
less this suggests that striatal allografts for HD patients will always
have only limited beneﬁts. The question then arises as to whether
these transient beneﬁts are worthwhile, given there are no disease
modifying therapies for this condition.
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What contribution does the non-striatal tissue in the graft
make to the efﬁcacy or otherwise of the transplant?
This is unknown, as attempts to increase the yield of striatal
tissue in the transplant have failed to translate into behavioral ben-
eﬁts, probably because the selective dissections undertaken to do
this remove a critical populationof cells that formavital functional
component of the transplant. Nevertheless it is clearly important
to know what contribution these non-striatal populations of cells
make to the efﬁcacy or otherwise of the graft (Freeman et al., 2011),
and this will become more of an issue as we move toward the pro-
duction of striatal neurons from stem cells sources (Dunnett and
Rosser, 2007). For the moment, all we can say is that the role of
the non-striatal tissue to the survival, integration, and efﬁcacy of
WGE striatal transplants is unknown.
If neural grafting is to be attempted inHD,when in the disease
process should it be done?
This raises a number of important issues to do with how novel
therapeutics of an invasive nature can be done in chronic neu-
rodegenerative disorders of the CNS. The rationale for neural
allografting is to replace the striatal tissue lost to the disease
process and so one could argue that the tissue should be grafted
when the striatum has signiﬁcant atrophy in patients with mod-
erately advanced disease. This though brings with it a number of
issues; (a) how do you neurosurgically place tissue into a signif-
icantly atrophied structure; (b) how can that tissue be expected
to recreate circuits when most of the components of that circuit
have been lost; (c) is it sensible to place tissue in an environ-
ment where the disease process is active; ﬁnally (d) how can the
patient be consented at a stage of disease when they have sig-
niﬁcant cognitive deﬁcits. Conversely if you go for very early
stage disease then you run the risk of; (a) causing or exacerbat-
ing striatal damage with sequelae to the patient; and (b) treating
a stage of disease that is not that problematic to the patient.
Thus, it would seem logical to pick some intermediate stage
between these two stages and although exactly which stage this
would be is unclear, it would probably represent early-mild disease
stages.
Why bother using such an approach when a more logical one
would be to target the pathogenic cascade downstream of the
mutant gene and the protein it codes for?
Ultimately the cure for HD will come from better understand-
ing the pathogenic pathway and blocking the disease process
using a cocktail of agents. However, there are currently no dis-
ease modifying agents for HD, despite several attempts to ﬁnd
one including studies with Co-enzyme Q10; remacemide; rilu-
zole, EPA, creatine, lamotrigine, baclofen, idebenone and d-alpha-
tocopherol (Shoulson et al., 1989; Peyser et al., 1995; Ranen
et al., 1996; Kremer et al., 1999; Huntington Study Group, 2001;
Verbessem et al., 2003; Landwehrmeyer et al., 2007; Hunting-
ton Study Group TREND-HD Investigators, 2008; Mestre et al.,
2009). As such neural grafting must still be seen as a possi-
ble therapy, especially since it seeks to replace lost cells, not
stop a disease process and thus could be used together with
disease modifying therapies in some instances. Whether it has
any real beneﬁts in HD is unproven, and until such time as
this is resolved, it should still be considered as one therapeutic
strategy.
How can the beneﬁts of cell therapy be properly assessed in
small numbers of HD patients, each of whom may progress rather
differently from each other?
The optimal way to do any cell therapy trial for any neurode-
generative disorder of the CNS is not known, as the diseases
are not easy to monitor; vary from patient to patient and over
time; studies involve small numbers of patients; rely on data from
imperfect animal models and often seek to ﬁnd quick solutions
in complex diffuse disease processes. Fetal striatal allografts and
HD are no exception to this, as although the disease can be diag-
nosed with absolute conﬁdence based on a genetic test in the
right clinical context, its natural history is not properly known.
Thus individual patients with HD follow different trajectories
for reasons that are not clear, although work is being done to
identify disease modiﬁers – from both a genetic and non-genetic
perspective. The best controls in small trials may be the patient
themselves but recently it has been suggested that disease pro-
gression varies as a function of disease stage, and is not linear
(Tabrizi et al., 2011). This inability to understand what controls
and predicts disease progression is a major issue, especially as it
is now becoming clear that environmental factors may improve
graft function (Brasted et al., 2000) as well as have effects on the
disease course (van Dellen et al., 2000, 2008; Nithianantharajah
and Hannan, 2006) in experimental models of disease and repair
in HD.
Ultimately the best way to do cell therapy studies inHD is either
to:
(a) use larger numbers with a delayed start design as has been
done in the on-going transplant study in France (see text
Footnote 1). Whilst an obvious solution, this is not straight-
forward given the variability of disease onset and progression,
for which a large cohort is not immune, along with the ethical
concerns of undertaking irreversible experimental therapies
in large numbers of patients;
(b) use intensive multi-modal assessments in small numbers of
patients and ascertainwhether they all point in the same direc-
tion (Reuter et al., 2008); This adoption of multiple end points
is useful, although if one has discordant results it will then be
important to know which is the more meaningful change and
this may prove difﬁcult. In addition, unlike the use of disease
modifying therapies, neural grafts in HD currently are used to
repair the brain and not change the underlying neuropatho-
logical process and as such changes in any biomarkermeasures
may not be informative;
(c) use very long follow up times (Reuter et al., 2008; Politis et al.,
2010). This is useful but is complicated by the fact that long-
term follow up brings with it the problems of avoiding the
introduction of any symptomatic drugs which will alter some
disease measures.
Which of these approaches one adopts is dependent to some extent
on what is being trialed, as safety is paramount in these studies
and the amount of data that speaks to that, or is already known,
determines the risk one can take with patient cohorts. However
the challenge of doing experimental therapeutics in neurodegen-
erative disorders of the CNS such as HD remains controversial,
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but indeﬁnite follow up of small numbers of intensely studied
patients currently represents the best approach, as has been seen
in trials of ventral mesencephalic grafting in PD (Politis et al.,
2010).
CONCLUSION
The use of fetal striatal tissue as a therapeutic strategy for HD has
a long history experimentally, but clinically the data is lacking as to
whether it really works. The experimental work goes back 30 years
and has mainly been based on lesion models of HD, with rela-
tively little work having been done in the newer transgenic model
of HD. These newer transgenic models suffer from an absence of
cell loss, but many may regard these as being more akin to the
clinical scenario. Thus the failure to show beneﬁts from grafting
in the R6/2 mouse model (Dunnett et al., 1998) may be a more
realistic approach, although the rate at the disease progresses in
these animals makes the interpretation more difﬁcult. Indeed fur-
ther studies need to be done in the more slowly progressing newer
transgenic animals before any conclusions can be drawn on the
efﬁcacy of fetal striatal allografting in this model of disease. What
the experimental studies in the striatal lesion models of HD have
shown, is that fetal striatal tissue can survive, differentiate appro-
priately,make connections, and circuits and restore behavior when
grafted into such a lesion.What remains unresolved is whether this
is possible when other structures in these circuits are also involved
in the disease process.
In this review we have laid out the rationale and basis for the
clinical studies that have adopted this approach, and highlighted
that much of this work was done in the pre-gene era when the dis-
ease was thought to have a much more exclusive striatal pathology.
The clinical studies that have subsequently been undertaken have
been done with differing degrees of rigor and produced mixed
results, but with little evidence to date that it produces long-term
beneﬁts in the majority of patients. This, coupled to the emerg-
ing post-mortem data in some of these patients, suggests that this
approach may not be the optimal therapeutic strategy for treating
HD. However, until clear evidence emerges of disease modifying
therapies for HD, it remains one possible strategy and could even
be used in conjunction with such treatments as a way of repair-
ing and retarding the disease. Ultimately, though, neural striatal
allografting is only treating one part of a much more diffuse dis-
ease process and as such will never be a cure for this devastating
disorder of the CNS.
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